Metoprolol Tartrate 166 57664 0166 58 Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
Metoprolol tartrate is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1) Angina Pectoris. ( 1.2) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients. ( 1.3)
What should I know before taking it?
Metoprolol tartrate is contraindicated in severe bradycardia, second or third degree heart block, cardiogenic shock, systolic blood pressure <100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.
What important warnings are listed?
Abrupt cessation may exacerbate myocardial ischemia. ( 5.1) Heart Failure: Worsening cardiac failure may occur. ( 5.2) Bronchospastic Disease: Avoid beta-blockers. ( 5.3) Pheochromocytoma: Initiate therapy with an alpha blocker. ( 5.4) Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non- cardiac surgery. Do not routinely withdraw chronic beta-blocker therapy prior to surgery. ( 5.5, 6.1) Diabetes: May mask symptoms of hypoglycemia. ( 5.6) Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. ( 5.7) Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency. ( 5.9)
How is this medication usually taken?
Metoprolol tartrate tablets, USP is supplied as: The 25 mg tablets are White to off white round, biconvex tablets debossed with R 25 on one side and scored on the other side. The 37.5 mg tablets are White to off white round, biconvex tablets debossed with R 375 on one side and scored on the other side. The 50 mg tablets are White to off white round, biconvex tablets debossed with R 50 on one side and scored on the other side. The 75 mg tablets are White to off white round, biconvex tablets debossed with R 75 on one side and scored on the other side. The 100 mg tablets are White to off white round, biconvex tablets debossed with R 100 on one side and scored on the other side.
What side effects are listed?
The following adverse reactions are described elsewhere in labeling: Worsening angina or myocardial infarction [see Warnings and Precautions (5)] Worsening heart failure [see Warnings and Precautions (5)]. Worsening AV block [see Contraindications (4)].
What interactions are listed?
Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7.1) Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. ( 7.2) CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7.3) Concomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. ( 7.4) Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7.4)
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bc7d371-6057-a9dc-e063-6394a90a6a9c
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.